Efficacy and Safety of Albendazole in Hookworm-infected Preschool-aged Children, School-aged Children, and Adults in Côte d'Ivoire: A Phase 2 Randomized, Controlled Dose-finding Trial.
Côte d’Ivoire
albendazole
drug safety
hookworm
soil-transmitted helminthiasis
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
15 07 2021
15 07 2021
Historique:
received:
23
04
2020
pubmed:
16
7
2020
medline:
5
8
2021
entrez:
16
7
2020
Statut:
ppublish
Résumé
Infections with hookworms affect about half a billion people worldwide. Recommended therapy includes 400 mg of albendazole, which is moderately efficacious. Higher doses have been rarely assessed. A randomized, controlled dose-finding trial was conducted in Côte d'Ivoire with the aim of recruiting 120 preschool-aged children (PSAC), 200 school-aged children (SAC), and 200 adults. Eligible PSAC were randomized 1:1:1 to 200 mg, 400 mg, or 600 mg of albendazole; the other age groups were randomized 1:1:1:1:1 to placebo or 200 mg, 400 mg, 600 mg, or 800 mg. The primary outcome was cure rates (CRs) assessed 14-21 days post-treatment by quadruplicate Kato-Katz thick smears. Hyperbolic Emax models were used to determine dose-response. 38 PSAC, 133 SAC, and 196 adults were enrolled. In adults, predicted CRs increased with ascending doses of albendazole, with a CR of 74.9% (95% confidence interval [CI], 55.6%-87.7%) in the 800-mg arm. Observed CRs increased with ascending doses of albendazole reaching a maximum of 94.1% (95% CI, 80.3%-99.3%). In SAC, the predicted dose-response curve increased marginally, with CRs ranging from 64.0% in the 200-mg arm to 76.0% in the 800-mg arm. Sample size in PSAC was considered too small to derive meaningful conclusions. 10.7% and 5.1% of participants reported any adverse event at 3 hours and 24 hours post-treatment, respectively. A single 800-mg albendazole dose provides higher efficacy against hookworm and is well tolerated in adults and should be considered for community-based strategies targeting adults. For PSAC and SAC, current recommendations suffice. NCT03527745.
Sections du résumé
BACKGROUND
Infections with hookworms affect about half a billion people worldwide. Recommended therapy includes 400 mg of albendazole, which is moderately efficacious. Higher doses have been rarely assessed.
METHODS
A randomized, controlled dose-finding trial was conducted in Côte d'Ivoire with the aim of recruiting 120 preschool-aged children (PSAC), 200 school-aged children (SAC), and 200 adults. Eligible PSAC were randomized 1:1:1 to 200 mg, 400 mg, or 600 mg of albendazole; the other age groups were randomized 1:1:1:1:1 to placebo or 200 mg, 400 mg, 600 mg, or 800 mg. The primary outcome was cure rates (CRs) assessed 14-21 days post-treatment by quadruplicate Kato-Katz thick smears. Hyperbolic Emax models were used to determine dose-response.
RESULTS
38 PSAC, 133 SAC, and 196 adults were enrolled. In adults, predicted CRs increased with ascending doses of albendazole, with a CR of 74.9% (95% confidence interval [CI], 55.6%-87.7%) in the 800-mg arm. Observed CRs increased with ascending doses of albendazole reaching a maximum of 94.1% (95% CI, 80.3%-99.3%). In SAC, the predicted dose-response curve increased marginally, with CRs ranging from 64.0% in the 200-mg arm to 76.0% in the 800-mg arm. Sample size in PSAC was considered too small to derive meaningful conclusions. 10.7% and 5.1% of participants reported any adverse event at 3 hours and 24 hours post-treatment, respectively.
CONCLUSIONS
A single 800-mg albendazole dose provides higher efficacy against hookworm and is well tolerated in adults and should be considered for community-based strategies targeting adults. For PSAC and SAC, current recommendations suffice.
CLINICAL TRIALS REGISTRATION
NCT03527745.
Identifiants
pubmed: 32668456
pii: 5872018
doi: 10.1093/cid/ciaa989
pmc: PMC8282316
doi:
Substances chimiques
Anthelmintics
0
Albendazole
F4216019LN
Banques de données
ClinicalTrials.gov
['NCT03527745']
Types de publication
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e494-e502Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Parasit Vectors. 2015 Feb 05;8:82
pubmed: 25652120
BMJ. 2017 Sep 25;358:j4307
pubmed: 28947636
Acta Trop. 2020 Jan;201:105214
pubmed: 31600519
Rev Inst Med Trop Sao Paulo. 1972 Nov-Dec;14(6):397-400
pubmed: 4675644
Lancet. 2019 May 18;393(10185):2039-2050
pubmed: 31006575
Am J Trop Med Hyg. 2013 Jul;89(1):23-31
pubmed: 23690551
Trans R Soc Trop Med Hyg. 2010 Feb;104(2):129-32
pubmed: 19926104
Parasit Vectors. 2014 Jan 21;7:37
pubmed: 24447578
Parasitol Today. 2000 Feb;16(2):71-4
pubmed: 10652492
Am J Trop Med Hyg. 2015 May;92(5):959-66
pubmed: 25758650
PLoS Med. 2005 Mar;2(3):e67
pubmed: 15783256
Parasitology. 2000;121 Suppl:S113-32
pubmed: 11386684
Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):88-98
pubmed: 18165479
Lancet. 2018 Nov 10;392(10159):1859-1922
pubmed: 30415748
Lancet. 2018 Jan 20;391(10117):252-265
pubmed: 28882382
PLoS Negl Trop Dis. 2018 Jan 18;12(1):e0006166
pubmed: 29346377
Clin Infect Dis. 2019 Aug 16;69(5):845-852
pubmed: 30496350
PLoS Negl Trop Dis. 2018 Apr 26;12(4):e0006296
pubmed: 29698486
Nat Rev Dis Primers. 2016 Dec 08;2:16088
pubmed: 27929101
PLoS Negl Trop Dis. 2016 Sep 08;10(9):e0004922
pubmed: 27607360
Parasit Vectors. 2015 Nov 05;8:570
pubmed: 26542226
Stat Med. 2009 Jan 30;28(2):274-92
pubmed: 19012269
Parasitology. 2000;121 Suppl:S39-50
pubmed: 11386690
Antimicrob Agents Chemother. 2014 May;58(5):2535-40
pubmed: 24550339
PLoS One. 2011;6(9):e25003
pubmed: 21980373
N Engl J Med. 2004 Aug 19;351(8):799-807
pubmed: 15317893
Acta Trop. 2003 May;86(2-3):141-59
pubmed: 12745134
Adv Parasitol. 2016;94:133-198
pubmed: 27756454